These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 2770020)
1. [Normoglycemic control by artificial pancreas in patients with pancreatic diabetes or with primary diabetes mellitus--analysis of patterns of insulin infusion and nocturnal glucose infusion]. Yoshida Y; Koizumi M; Abe N; Ishizuka J; Sanoyama K; Goto Y Nihon Shokakibyo Gakkai Zasshi; 1989 Mar; 86(3):786-92. PubMed ID: 2770020 [TBL] [Abstract][Full Text] [Related]
2. Use of the artificial B-cell (Biostator) in improving insulin therapy in unstable insulin-dependent diabetes. Ratzmann KP; Bruns W; Schulz B; Zander E Diabetes Care; 1982; 5(1):11-7. PubMed ID: 6754298 [TBL] [Abstract][Full Text] [Related]
3. The metabolic and hormonal response to acute normoglycaemia in type 1 (insulin-dependent) diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas). Nosadini R; Noy GA; Nattrass M; Alberti KG; Johnston DG; Home PD; Orskov H Diabetologia; 1982 Sep; 23(3):220-8. PubMed ID: 6751902 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of continuous subcutaneous insulin infusion in unstable diabetes secondary to chronic pancreatitis: a case report. Cavallo-Perin P; Pagano G Acta Diabetol Lat; 1983; 20(1):89-91. PubMed ID: 6858546 [No Abstract] [Full Text] [Related]
5. Predicting nocturnal hypoglycemia in patients with type I diabetes treated with continuous subcutaneous insulin infusion. Schiffrin A; Suissa S Am J Med; 1987 Jun; 82(6):1127-32. PubMed ID: 3605131 [TBL] [Abstract][Full Text] [Related]
6. Glucose counterregulation in diabetes secondary to chronic pancreatitis. Larsen S; Hilsted J; Philipsen EK; Tronier B; Christensen NJ; Damkjaer Nielsen M; Worning H Metabolism; 1990 Feb; 39(2):138-43. PubMed ID: 1967815 [TBL] [Abstract][Full Text] [Related]
7. Absence of exercise-induced hypoglycaemia in type i (insulin-dependent) diabetic patients during maintenance of normoglycaemia by short-term, open-loop insulin infusion. Martin MJ; Robbins DC; Bergenstal R; LaGrange B; Rubenstein AH Diabetologia; 1982 Oct; 23(4):336-42. PubMed ID: 6754517 [TBL] [Abstract][Full Text] [Related]
8. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Weinzimer SA; Steil GM; Swan KL; Dziura J; Kurtz N; Tamborlane WV Diabetes Care; 2008 May; 31(5):934-9. PubMed ID: 18252903 [TBL] [Abstract][Full Text] [Related]
9. Short-term of the artificial beta-cell (Biostator) on pancreatic glucagon response in insulin-dependent diabetic (IDDM). Ratzmann KP; Schneider U; Besch W; Heinke P Exp Clin Endocrinol; 1984 Jul; 84(1):91-8. PubMed ID: 6383851 [TBL] [Abstract][Full Text] [Related]
10. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393 [TBL] [Abstract][Full Text] [Related]
11. Practical closed-loop insulin delivery. A system for the maintenance of overnight euglycemia and the calculation of basal insulin requirements in insulin-dependent diabetics. White NH; Skor D; Santiago JV Ann Intern Med; 1982 Aug; 97(2):210-3. PubMed ID: 7103278 [TBL] [Abstract][Full Text] [Related]
12. Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Nosadini R; del Prato S; Tiengo A; Duner E; Toffolo G; Cobelli C; Faronato PP; Moghetti P; Muggeo M Diabetes; 1982 Apr; 31(4 Pt 1):346-55. PubMed ID: 6759250 [TBL] [Abstract][Full Text] [Related]
14. Examination of the role of the pituitary-adrenocortical axis, counterregulatory hormones, and insulin clearance in variable nocturnal insulin requirements in insulin-dependent diabetes. Skor DA; White NH; Thomas L; Shah SD; Cryer PE; Santiago JV Diabetes; 1983 May; 32(5):403-7. PubMed ID: 6341122 [TBL] [Abstract][Full Text] [Related]
15. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845 [TBL] [Abstract][Full Text] [Related]
16. 24-hour blood glucose profiles in insulin-dependent diabetics treated with intravenous insulin infusion systems. A comparison between closed- and open-loop systems. Deckert T; Bojsen J; Christiansen JS; Kølendorf K; Svendsen PA; Andersen AR Acta Med Scand; 1980; 208(6):451-8. PubMed ID: 7008508 [TBL] [Abstract][Full Text] [Related]
17. Insulin production rate in normal man as an estimate for calibration of continuous intravenous insulin infusion in insulin-dependent diabetic patients. Waldhäusl WK; Bratusch-Marrain PR; Francesconi M; Nowotny P; Kiss A Diabetes Care; 1982; 5(1):18-24. PubMed ID: 6754299 [TBL] [Abstract][Full Text] [Related]
18. Metabolic and hormonal responses during a glucose controlled insulin infusion (Biostator) in subjects with impaired glucose tolerance. Ratzmann KP; Schneider U; Peters U; Ziegler M; Schulz B Exp Clin Endocrinol; 1984 May; 83(3):334-42. PubMed ID: 6381073 [TBL] [Abstract][Full Text] [Related]
19. Predicting insulin requirements for a portable insulin pump using the Biostator. Evidence for reversible insulin resistance in poorly controlled type I diabetics. Mayfield RK; Sullivan FM; Colwell JA; Wohltmann HJ Diabetes; 1983 Oct; 32(10):908-14. PubMed ID: 6352376 [TBL] [Abstract][Full Text] [Related]